Patrick Forde, Professor at Johns Hopkins University and Co-Director of the Division of Upper Aerodigestive Malignancies at the Sidney Kimmel Comprehensive Cancer Center, shared an article by Anwen Xiong, et al. on X:
“Now published!
PD-1 VEGF bispecific doubles PFS in 1st line advanced non-small cell lung cancer.
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China – The Lancet.”
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.
Authors: Anwen Xiong, et al.
